DaVita Celebrates 25 Years of Clinical Advancement in Chronic Disease Care, Expands Decentralized Recruitment Services.

DaVita Clinical Research (DCR) celebrates 25 years of advancing kidney care through over 500 clinical trials and significant contributions to the field. DaVita operates 3,175 outpatient dialysis centers worldwide, serving approximately 283,100 patients, and has expanded decentralized recruitment services to increase diversity in clinical trials. The company has contributed to every FDA-approved drug for end-stage kidney disease and has published 180 manuscripts and 520 research abstracts.

Denver, Aug. 27, 2025 — DaVita, a leading provider of comprehensive kidney care, celebrated 25 years of groundbreaking research through its wholly owned research arm, DaVita Clinical Research (DCR). Over the past quarter-century, DCR has played a pivotal role in advancing kidney care, driving access to new therapies, and improving clinical outcomes.

DCR has conducted over 500 clinical trials across 250 research sites, with 8,900 participants in the last five years alone [2]. These trials have contributed to every FDA-approved drug for end-stage kidney disease (ESKD) and have resulted in the publication of 180 manuscripts and 520 research abstracts [2]. The research arm has also been instrumental in revising clinical practice guidelines, including a revised approach to anemia management now widely adopted across the nephrology field [1].

One of DCR's notable achievements is its role in the COVID-19 response. DaVita contributed to vaccine trials and hosted initial rounds of vaccinations for frontline workers at its DCR headquarters, ultimately participating in a federal effort to support access to vaccines for hundreds of thousands of at-risk patients at their existing point of care [1].

DaVita's commitment to inclusive research is evident in its implementation of decentralized recruitment services in 2024. This initiative aims to expand trial access to underserved research locations, thereby increasing diversity in clinical trials [1]. As of June 30, 2025, DaVita serves approximately 283,100 patients at 3,175 outpatient dialysis centers worldwide, with 2,662 centers located in the United States and 513 centers in 13 other countries [2].

While DaVita's research division has made significant strides, the company has also faced challenges. In April, DaVita was noted by the Department of Health and Human Services to have had data from 2.7 million individuals compromised following an Interlock ransomware attack. However, operations were only temporarily disrupted, and critical care delivery remained uninterrupted by the incident [3].

Despite these challenges, DaVita's commitment to innovation and patient care remains steadfast. The company continues to expand its global research network, accelerating innovation and creating new opportunities to advance kidney care and related therapies.

References:
[1] https://www.prnewswire.com/news-releases/davita-honors-25-years-of-clinical-advancement-in-chronic-disease-care-302539438.html
[2] https://www.stocktitan.net/news/DVA/da-vita-honors-25-years-of-clinical-advancement-in-chronic-disease-qqe1fuucgk47.html
[3] https://www.scworld.com/brief/toll-of-davita-ransomware-hack-reaches-2-7m